Antares Pharma Inc License [Member] Antares Pharma, Inc. License Represents information pertaining to the Antares Pharma,Inc. License. Represents the warrant expense recognized in the reporting period. Class of Warrant or Rights Expense Stock warrant expense Wake Forest License [Member] Wake Forest License Represents information pertaining to the Wake Forest License. Number of Patents for Which Option for Licence is Exercised Number of patents for which an option for an exclusive license is exercised Represents the number of patents for which an option for an exclusive license is exercised. Nature of Business [Table] Disclosure pertaining to description of nature and location of business. Number of Consecutive Business Days for which Common Stock Bid Price is below Minimum Requirement Number of consecutive business days for which bid price for common stock had closed below the minimum price per share required for continued inclusion on The NASDAQ Global Market under NASDAQ Listing Rule 5450(a)(1) Represents the number of consecutive business days for which bid price for common stock had closed below the minimum price per share required for continued inclusion on The NASDAQ Global Market under NASDAQ Listing Rule 5450(a)(1). Share Price to be Maintained for Inclusion in Global Market Price per share required for continued inclusion on The NASDAQ Global Market (in dollars per share) Represents price per share required for continued inclusion on The NASDAQ Global Market. Number of Days Afforded to Regain Complaince with Minimum Bid Price Requirement Number of days afforded to regain compliance with minimum bid price requirement Represents the number of days afforded to regain compliance with the minimum bid price requirement pursuant to NASDAQ Listing Rule 5810(c)(3)(A). Number of consecutive business days for which minimum bid closing price have to be maintained Represents the number of consecutive business days for which the entity has to maintain minimum bid closing price in order to regain compliance. Number of Consecutive Business Days to Maintain Minimum Bid Closing Price Additional Grace Period to Regain Compliance if Stock Listing is Transferred to NASDAQ Capital Market Additional grace period to regain compliance if stock listing is transferred to NASDAQ Capital Market Represents additional grace period to regain compliance for which the entity would be eligible if the entity transfers its common stock listing to The NASDAQ Capital Market and meets certain other requirements. Nature of Business [Line Items] Description of business Cell Genesys Represents information pertaining to Cell Genesys, Inc. Cell Genesys Inc [Member] Reclassification [Abstract] Reclassifications FDIC Insured Account Percentage of Balance Insured FDIC-insured accounts, percentage of balance insured Represents the percentage of funds deposited into FDIC-insured accounts that is insured. Non computer Equipment [Member] Non-computer equipment Represents long-lived depreciable assets that are used to produce goods and services. Reverse Stock Split Conversion Ratio Reverse split ratio Represents the conversion ratio used in the calculation of a reverse stock split. Capital Stock [Abstract] Capital stock Number of Vaccines Granted with FDA Orphan Drug Designation Number of cancer vaccines that have been granted FDA orphan drug designation Represents the number of cancer vaccines developed by the entity which have been granted FDA orphan drug designation. Number of Phase I and Phase II Clinical Trials Number of Phase I and Phase II clinical trials Represents the number of Phase I and Phase II clinical trials for the treatment of various cancers in which the entity is participating. Number of Debt Instrument, Holders to Whom Shares are Issued Number of holders of debt instrument to whom shares are issued by the entity Represents the number of holders of debt instrument to whom shares are issued by the entity. Represents the number of series of convertible notes assumed by the entity. Number of Series of Convertible Notes Assumed Number of series of convertible notes assumed in merger Number of Board Members Designated by the Entity Represents the number of Board members of investee to be designated by the entity as minority shareholder. Number of Board members to be designated DESCRIPTION OF BUSINESS LIQUIDITY AND CAPITAL RESOURCES Liquidity and Capital Resources [Line Items] Liquidity and capital resources LICENSE AGREEMENTS LICENSE AGREEMENTS License Agreements Disclosure [Text Block] The entire disclosure for all or part of the information related to license agreements. Document and Entity Information Net proceeds from issuance of shares through an underwritten public offering Proceeds from issuance of common stock by underwritten offering Proceeds from Issuance of Common Stock by Underwritten Public Offering Represents the proceeds, net of underwriters' discounts, commissions and offering expenses, from the issuance of stock through an underwritten public offering. Excess Consideration Paid over Fair Value Excess consideration paid over fair value Amount of expenses charged against earnings during the period related to business combination, which is the excess of the cost of the acquired entity over the fair value assigned to assets acquired and liabilities assumed. Issuance of Common Shares [Abstract] Issuance of common shares Stock Issued During Period Value, Common Shares and Warrants Registered direct offerings of common shares and warrants, net Value of common stock and warrants issued during the reporting period. Adjustments to Additional Paid in Capital Credit Equity Financing Facility Credit equity financing facility Increase in Additional Paid-in-Capital pursuant to credit equity financing facility under which entity could borrow funds. Further, convertible notes are subject to repurchase by entity at each holder's option. Number of common shares and warrants issued during the reporting period. Stock Issued During Period, Common Shares and Warrants Registered direct offerings of common shares and warrants, net (in shares) Registered direct offerings of common shares and warrants Stock Issued During Period Value, Warrants Exercised Warrant exercises - various Value stock issued during the period as a result of the exercise of warrants. Purchase Commitment Cumulative Payments to Acquire Machinery Amount paid Represents the cumulative amount paid by the entity for purchase of machinery. Stock Issued During Period Shares, Warrants Exercised Warrant exercises - various (in shares) Number of shares of stock issued during the period as a result of the exercise of warrants. Number of shares of stock issued during the period as a result of the exercise of warrants Noncash Investment Investment - non-cash The value of investments in noncash investing or financing activities. Consolidation Basis of Presentation and Accounting Policies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Consolidation Basis of Presentation and Accounting Policies [Text Block] The entire disclosure for consolidation, basis of presentation and accounting policies. Repayments of Short Term Convertible Debt Cash paid for convertible note repayment The cash outflow from the conversion at maturity of a short-term debt instrument which was exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Liquidity and Capital Resources [Text Block] LIQUIDITY AND CAPITAL RESOURCES This element may be used for the entire disclosure related to entity's liquidity and capital resources, which includes description of entity's revenue, stockholders' equity, including other comprehensive income, and cash and cash equivalents disclosure. Schedule of Liquidity and Capital Resources [Table] Represents details pertaining to liquidity position and availability of capital resources to the entity. Represents convertible senior notes bearing an interest of 3.125 percent which mature in 2013. Convertible Senior Notes 3.125 Percent Due 2013 [Member] 2013 Notes Schedule of key assumptions used to establish the value of the 2013 Notes Tabular disclosure of the significant assumptions used during the period to estimate the fair value of debt instruments. Schedule of Fair Value Assumptions Used for Debt Instruments [Table Text Block] Convertible Senior Notes 3.125 Percent Due 2011 [Member] 2011 Notes Represents convertible senior notes bearing an interest of 3.125 percent which mature in 2011. Long Term Debt, Redemption Price as Percentage of Principal Amount, Option to Holder Percentage of principal amount at which the holder may require the entity to repurchase notes Represents the percentage of principal amount used in the computation of the redemption price at which the holders may require the entity to repurchase the debt instruments on or after specified dates in case a fundamental change (as defined in the indenture) occurs. Percentage of principal amount at which the entity may redeem notes in whole or in part Represents the percentage of principal amount used in the computation of the redemption price at which the entity may redeem some or all of the debt instruments on or after specified dates. Long Term Debt, Redemption Price as Percentage of Principal Amount Represents discount rate for principal payments in cash, an assumption used in valuation of an instrument. Fair Value Assumptions Discount Rate Discount rate for principal payments in cash (as a percent) Debt Instrument Conversion Obligation Common Stock Closing Sales Price as Percentage of Conversion Price Percentage of the closing sales price of the entity's common stock that the conversion price must exceed in order for the notes to be convertible Represents the percentage of the closing sales price of the entity's common stock for at least 20 days within 30 consecutive trading days that the closing sales price of the entity's common stock must exceed the conversion price in order for the debt instruments to be convertible. Number of days within 30 consecutive trading days in which the closing price of the entity's common stock must exceed the conversion price for the notes to be redeemable Represents the number of trading days within a period of 30 consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible. Debt Instrument Conversion Obligation Common Stock Closing Sales Price Number of Trading Days Debt Instrument Conversion Obligation Number of Consecutive Trading Days Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be redeemable Represents the number of consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the debt instruments to be convertible. Number of Products or Technologies Licensed by Entity as Alternative to Raising Additional Financing Number of products or technologies licensed by the entity as an alternative to raising additional financing Represents the number of products or technologies licensed by the entity as an alternative to raising additional financing. Aptar Pharma [Member] Aptar Pharma Represents the details pertaining to Aptar Pharma. Schedule of Business Acquisitions by Acquisition Purchase Price [Table Text Block] Schedule of purchase price of the merger Tabular disclosure of purchase price of acquisition. Business Acquisition Purchase Price Allocation Investments Investment in Ceregene Represents amount of acquisition cost of a business combination allocated to investment. Represents amount of acquisition cost of a business combination allocated to in-process research and development. Business Acquisition Purchase Price Allocation in Process Research and Development In-process research and development Business Acquisition Purchase Price Allocation Receivables Equipment and Other Assets Receivables, equipment and other assets Represents amount of acquisition cost of a business combination allocated to receivables, equipment and other assets. Business Acquisition Purchase Price Allocation Current Liabilities Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities Represents the amount of acquisition cost of a business combination allocated to accounts payable and accrued liabilities of the acquired entity. Deferred Tax Assets Deferred Financing Costs Deferred financing costs for tax Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred financing costs. Operating Loss Carryforwards Term Number of years for which net operating loss carryforwards are available to reduce future taxable income Represents the number of years for which net operating loss carryforwards are available to reduce future taxable income. Percentage of Provision of Valuation Allowance to Reduce Deferred tax Assets Provision of valuation allowance to reduce deferred tax assets (as a percent) Represents the percentage of provision of valuation allowance to reduce deferred tax assets. Fractional Share Adjustment Represents the fractional share adjustments. June 1, 2012 Fractional Share Adjustment Number of Stockholder Approved Equity Based Compensation Plans Number of stockholder-approved equity-based compensation plans Represents number of stockholder approved equity based compensation plans under which stock options have been granted. Plan 2008 [Member] 2008 Plan Represents information pertaining to the 2008 equity compensation plan of the entity. 1998 Plan Represents information pertaining to the 1998 equity compensation plan of the entity. Plan 1998 [Member] Share Based Compensation Arrangement by Share Based Payment Award, Award Contractual Term Contractual term of stock options Represents the contractual term of stock-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Weighted Average Remaining Term Share Based Compensation Arrangement by Share Based Payment Award Options Intrinsic Value [Abstract] Aggregate Intrinsic Value Undesignated Preferred Stock [Member] Undesignated preferred stock Represents information pertaining to undesignated preferred stock. Class of Warrant Issued on 8 March 2011 Due 8 March 2014 [Member] Issued on March 8, 2011 and expired on March 8, 2014 Represents information pertaining to warrants issued on March 8, 2011 and expired on March 8, 2014. Class of Warrant Issued on 8 March 2011 Due 9 June 2014 [Member] Issued on March 8, 2011 and expired on June 9, 2014 Represents information pertaining to warrants issued on March 8, 2011 and expired on June 9, 2014. Class of Warrant Issued on 8 March 2010 Due 8 September 2015 [Member] Issued on March 8, 2010 and expired on September 8, 2015 Represents information pertaining to warrants issued on March 8, 2010 and expired on September 8, 2015. Class of Warrant Issued on 8 March 2010 Due 9 June 2014 [Member] Issued on March 8, 2010 and expired on June 9, 2014 Represents information pertaining to warrants issued on March 8, 2010 and expired on June 9, 2014. Class of Warrant Issued on 23 June 2010 Due 23 June 2015 [Member] Issued on June 23, 2010 and expired on June 23, 2015 Represents information pertaining to warrants issued on June 23, 2010 and expired on June 23, 2015. Class of Warrant Issued on 23 June 2010 Due 9 June 2015 [Member] Issued on June 23, 2010 and expired on June 9, 2015 Represents information pertaining to warrants issued on June 23, 2010 and expired on June 9, 2015. Class of Warrant Issued on 30 December 2010 Due 30 December 2015 [Member] Issued on December 30, 2010 and expired on December 30, 2015 Represents information pertaining to warrants issued on December 30, 2010 and expired on December 30, 2015. Class of Warrant Issued on 30 December 2010 Due 9 June 2015 [Member] Issued on December 30, 2010 and expired on June 9, 2015 Represents information pertaining to warrants issued on December 30, 2010 and expired on June 9, 2015. Common Stock Number of Votes Per Share Number of votes per share, entitled to its holder Represents the number of votes per share, entitled to its holder. Common Stock Conversion Ratio Conversion ratio for conversion of units into common stock (as a percent) Represents the conversion ratio for converting shares of common stock into another class of common stock. Common Stock Conversion Price Exchange price per share (in dollars per share) Represents the conversion price for converting shares of common stock into another class of common stock. Stock Issued During Period Common Stock to Institutional Investors Shares of common stock issued to institutional investors Represents the shares of common stock issued to institutional investors. Warrants issued to purchase common stock in connection with registered direct offering (in shares) Purchase Price Per Share to Institutional Investors Purchase price at which shares are issued to institutional investors (in dollars per share) Represents the purchase price at which shares are issued to institutional investors. Gross Proceeds from Issuance of Common Stock Gross proceeds of common stock and warrants Represents the cash inflow from issuance of common stock and warrants, before deducting the expenses and fees incurred during issuance of common stock. Class of Warrant or Right Expiration Period Expiration period of warrants issued Represents the expiration period of class of warrants or rights issued. Placement Agent Warrants Issued During Period Common Stock Placement agent warrants issued (in shares) Represents the placement agent warrants issued to purchase shares of the entity's common stock. Number of Institutional Investors to Whom Registered Direct Offering made Number of institutional investors Represents the number of institutional investors to whom registered direct offerings were made to raise funds. Business Acquisition Option for Equity Interests Issued or Issuable for each Share of Acquiree Number of shares that may be received on conversion of each share of the acquiree entity (as a percent) Represents the number of shares that may be received on conversion of each share of acquiree. Business Acquisition Assumed Options Converted into Options to Purchase Shares Number of shares of the acquirer entity issued on conversion of assumed options into options Represents the number of shares of acquiree's assumed options, which were converted into options of the acquirer. Business Acquisition Weighted Average Exercise Price of Option Weighted average exercise price of option (in dollars per share) Represents the exercise price of shares of acquiree's assumed options, which were converted into options of the acquirer. Business Acquisition Assumed Warrants Converted into Warrants to Purchase Shares Number of shares of the acquirer entity issued on conversion of assumed warrants into warrants Represents the number of shares of acquiree's assumed warrants, which were converted into warrants of the acquirer. Class of Warrant Issued on 15 December 2008 Due 14 June 2014 [Member] Issued on December 15, 2008 and expired on June 14, 2014 Represents information pertaining to warrants issued on December 15, 2008 and expired on June 14, 2014. Class of Warrant Issued on 21 July 2009 Due 20 July 2012 [Member] Issued on July 21, 2009 and expired on July 20,2012 Represents information pertaining to warrants issued on July 21, 2009 and expired on July 20, 2012. Class of Warrant Issued on 13 August 2009 Due 12 August 2014 [Member] Issued on August 13, 2009 and expired on August 12, 2014 Represents information pertaining to warrants issued on August 13, 2009 and expired on August 12, 2014. Class of Warrant Issued on 13 August 2009 Due 9 June 2014 [Member] Issued on August 13, 2009 and expired on June 9, 2014 Represents information pertaining to warrants issued on August 13, 2009 and expired on June 9, 2014. Class of Warrant Issued on 14 October 2009 Due 1 April 2012 [Member] Issued on October 14, 2009 and expired on April 1, 2012 Represents information pertaining to warrants issued on October 14, 2009 and expired on April 1, 2012. Class of Warrant Issued on 22 November 2010 Due 21 November 2013 [Member] Issued on November 22, 2010 and expired on November 21, 2013 Represents information pertaining to warrants issued on November 22, 2010 and expired on November 21, 2013. Stock Share Warrants Expired Unexercised Number of shares of stock of which warrants expired unexercised Represents the number of shares of stock of which warrants expired unexercised. Warrants to Purchase Shares of Common Stock as Compensation for Investor Relation Warrants to purchase shares of common stock as compensation for investor relations services Represents the warrants to purchase shares of common stock as compensation for investor relations services. Period over Which Warrants Become Exercisable from Date of Grant Period over which warrants become exercisable from date of grant Represents the period over which warrants become exercisable from the date of grant. Stock Issued During Period Common Stock in Connection with Registered Direct Offerings Shares of common stock issued in connection with registered direct offerings Represents the shares of common stock in connection with registered direct offerings. Award Type [Axis] Amendment Description Amendment Flag Arrangements and Non-arrangement Transactions [Domain] Current Fiscal Year End Date Document Period End Date Entity [Domain] Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Legal Entity [Axis] Document Type Accounts Payable, Current Accounts payable Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Stock option expense Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash (used in) operations Adjustments to reconcile net loss to net cash (used in) operating activities Adjustments to Additional Paid in Capital, Warrant Issued Stock warrant expense Allocated Share-based Compensation Expense Stock-based compensation expense Total stock-based compensation expense Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Securities excluded from computation of earnings per share Antidilutive Securities, Name [Domain] Assets, Fair Value Disclosure Total Assets Assets, Current [Abstract] CURRENT ASSETS Assets [Abstract] ASSETS Assets, Current TOTAL CURRENT ASSETS Assets TOTAL ASSETS Assets, Fair Value Disclosure [Abstract] Assets: Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Basis of Accounting [Text Block] BASIS OF PRESENTATION Business Acquisition [Axis] Common stock acquired (as a percent) Business Acquisition, Percentage of Voting Interests Acquired Interest acquired (as a percent) Allocation of purchase price Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net [Abstract] Business Acquisition, Acquiree [Domain] Purchase price of the merger Business Acquisition, Cost of Acquired Entity, Purchase Price [Abstract] Total net assets acquired Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net Cash Business Acquisition, Purchase Price Allocation, Current Assets, Cash and Cash Equivalents Number of shares of common stock issued Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Number of shares of common stock issued in connection with merger ACQUISITION OF NET ASSETS OF CELL GENESYS Transaction costs of BioSante Business Acquisition, Cost of Acquired Entity, Transaction Costs Fair value of BioSante common stock issued Business Acquisition, Cost of Acquired Entity, Equity Interests Issued and Issuable Basis of Presentation Business Acquisition [Line Items] Acquisition Total purchase price Business Acquisition, Cost of Acquired Entity, Purchase Price Convertible senior notes Business Acquisition, Purchase Price Allocation, Notes Payable and Long-term Debt Business Combination Disclosure [Text Block] ACQUISITION OF NET ASSETS OF CELL GENESYS Additional disclosures Business Combination, Separately recognized Transactions, Additional Disclosures [Abstract] Capital Addition Purchase Commitments [Member] Gel Filling Machine Gel Packaging Machine Capital Expenditures Incurred but Not yet Paid Purchase of fixed assets on account, non-cash investing activity Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT END OF PERIOD Cash received in transaction Cash Acquired from Acquisition Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents [Abstract] Class of Warrant or Right [Table] Class of Warrant or Right, Outstanding Warrants to purchase shares of common stock outstanding and excercisable Stockholders' equity Class of Warrant or Right [Line Items] Class of Warrant or Right [Domain] Class of Stock [Line Items] Stockholders' equity Class of Warrant or Right [Axis] Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price (in dollars per share) Weighted average exercise price (in dollars per share) Per Share Exercise Price (in dollars per share) Class of Stock [Domain] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued (in shares) Number of Underlying Shares Of Common Stock License agreement Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] COMMITMENTS AND CONTINGENCIES Commitments Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Common stock Common Stock [Member] Common Stock Common Stock, Shares, Outstanding Capital stock, outstanding shares Shares Outstanding Common Stock, Shares, Issued Capital stock, issued shares Balance at beginning of period (in shares) Balance at end of period (in shares) Shares issued Common Stock, Value, Outstanding Capital stock Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Class C special stock Common Class C [Member] Class C Special Shares RETIREMENT PLAN Computer equipment Computer Equipment [Member] 2013 Contractual Obligation, Due in Second Year 2016 Contractual Obligation, Due in Fifth Year Schedule of future minimum maintenance payments due Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] 2015 Contractual Obligation, Due in Fourth Year 2012 Contractual Obligation, Due in Next Twelve Months 2014 Contractual Obligation, Due in Third Year Thereafter Contractual Obligation, Due after Fifth Year Minimum Amount Due Contractual Obligation, Fiscal Year Maturity [Abstract] Convertible Notes Payable, Noncurrent Long-term Convertible Senior Notes Long-term convertible senior notes Convertible Notes Payable [Member] 2013 Notes Convertible senior notes Convertible Debt, Fair Value Disclosures Fair value of convertible debt Investments Cost Method Investments, Policy [Policy Text Block] Costs and Expenses [Abstract] EXPENSES Costs and Expenses Total expenses Debt Instrument [Line Items] Convertible Senior Notes Convertible senior notes Schedule of Long-term Debt Instruments [Table] Debt Conversion, Original Debt, Amount Principal amount of debt cancelled Debt Disclosure [Text Block] CONVERTIBLE SENIOR NOTES CONVERTIBLE SENIOR NOTES Debt Instrument, Convertible, Conversion Price Conversion price (in dollars per share) Debt Instrument, Convertible, Number of Equity Instruments Number of shares of common stock receivable upon conversion Debt Instrument, Face Amount Principal amount Convertible Senior Notes Debt, Policy [Policy Text Block] Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Components of the Company's net deferred tax asset Deferred Tax Assets, Net of Valuation Allowance [Abstract] Tax basis in intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Net deferred tax asset Deferred Tax Assets, Net of Valuation Allowance Research & development credits Deferred Tax Assets, in Process Research and Development Total deferred tax asset Deferred Tax Assets, Gross Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Other Deferred Tax Assets, Other Stock option expense Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Valuation allowance Deferred Tax Assets, Valuation Allowance Contributions expensed Defined Contribution Plan, Cost Recognized Deposits Assets, Noncurrent Deposits Depreciation, Depletion and Amortization Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION Earnings Per Share, Diluted Diluted (in dollars per share) Loss per share: Earnings Per Share, Basic and Diluted [Abstract] Earnings Per Share, Basic Basic (in dollars per share) BASIC AND DILUTED NET LOSS PER SHARE (in dollars per share) Earnings Per Share, Basic and Diluted Basic and diluted (in dollars per share) Earnings Per Share [Text Block] BASIC AND DILUTED NET LOSS PER SHARE Basic and Diluted Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] BASIC AND DILUTED NET LOSS PER SHARE Loss per common share: Statutory federal income tax rate (as a percent) Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate Employee-related Liabilities, Current Accrued compensation Weighted-average period over which unrecognized compensation cost is expected to be recognized Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Stock option compensation expense for employees and non-employees Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized [Abstract] Unrecognized compensation cost (in dollars) Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options Equipment Equipment [Member] Equity Component [Domain] Estimate of Fair Value, Fair Value Disclosure [Member] Total Measurement Frequency [Axis] Fair Value by Asset Class [Domain] Fair Value Assumptions, Expected Volatility Rate Volatility of BioSante common stock (as a percent) Convertible note fair value adjustment Fair Value, Option, Changes in Fair Value, Gain (Loss) Convertible note fair value adjustment Fair value adjustment Fair Value, Hierarchy [Axis] Liability Class [Axis] Fair Value, Measurements, Recurring [Member] Recurring basis Fair Value, Measurement Frequency [Domain] Fair Value Assumptions, Risk Free Interest Rate Average risk-free rate (as a percent) Fair Value Measurements, Recurring and Nonrecurring [Table] Asset Class [Axis] Fair Value by Liability Class [Domain] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract] Assumptions to establish the value of the Notes Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value of assets and liabilities FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Option, Aggregate Differences, Long-term Debt Instruments Amount of difference between aggregate recorded fair value of the notes and their total stated principal amount Fair Value, Option, Credit Risk, Gains (Losses) on Liabilities Fair value adjustment attributable to the change in instrument specific credit risk Gain (Loss) on Sale of Property Plant Equipment Loss on disposal of equipment Loss on disposal of fixed assets General and Administrative Expense General and administration General and Administrative Expense [Member] General and administrative Instrument Type [Domain] Instrument [Axis] Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Condensed Statements of Operations Income Tax Disclosure [Text Block] INCOME TAXES INCOME TAXES Total income tax expense Income Tax Expense (Benefit) Other income Income tax benefit Tax at U.S. federal statutory rate Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate Difference in the provision for income taxes computed by applying the statutory income rate to pre-tax income Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract] Change in valuation allowance Income Tax Reconciliation, Change in Deferred Tax Assets Valuation Allowance State taxes, net of federal benefit Income Tax Reconciliation, State and Local Income Taxes Income Taxes Income Tax, Policy [Policy Text Block] Research and development credits Income Tax Reconciliation, Nondeductible Expense, Research and Development Other, net Income Tax Reconciliation, Other Adjustments Increase (Decrease) in Accounts Receivable Accounts receivable Changes related to accounts receivable Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities affecting cash flows from operations Changes in other assets and liabilities affecting cash flows from operations Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Prepaid expenses, deposits and other assets Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Accrued and unpaid interest payable on cancellation of debt Interest Payable Interest Expense Interest expense Interest Paid Interest paid, including acquired accrued interest Interest paid Interest income Investment Income, Interest Issuance of Stock and Warrants for Services or Claims Stock warrant expense - noncash Long-term Debt, Type [Domain] Long-term Debt, Type [Axis] LEASE ARRANGEMENTS Leases of Lessee Disclosure [Text Block] LEASE ARRANGEMENTS Legal Costs Legal Costs, Policy [Policy Text Block] Liabilities, Current TOTAL CURRENT LIABILITIES Liabilities, Fair Value Disclosure Total liabilities Liabilities, Current [Abstract] CURRENT LIABILITIES Liabilities TOTAL LIABILITIES Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Fair Value Disclosure [Abstract] Liabilities: Liabilities and Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY License Costs Licensing expense Licenses Revenue Licensing revenue Litigation Case Type [Domain] Litigation Case [Axis] Long-term Debt Total Long-term Debt, Fair Value Recorded fair value Long-term Debt, Fiscal Year Maturity [Abstract] Maturities of required principal payments by year Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Line Items] Commitment and contingencies Long-term Debt, Maturities, Repayments of Principal in Year Two 2013 2012 Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months Long-term Investments Investments Investment in Ceregene, Inc. accounted under cost method Investments balance Investments Long-term Investments [Abstract] Category of Item Purchased [Axis] Long-term Purchase Commitment, Category of Item Purchased [Domain] Long-term Purchase Commitment, Amount Amount of commitment to purchase machinery Loss Contingencies [Table] COMMITMENTS AND CONTINGENCIES Loss Contingencies [Line Items] Maximum [Member] High end of range Maximum Minimum [Member] Low end of range Minimum Money Market Funds [Member] Money market fund Nature of Operations [Text Block] DESCRIPTION OF BUSINESS Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] CASH FLOWS PROVIDED BY FINANCING ACTIVITIES Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash (used in) operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] CASH FLOWS (USED IN) OPERATING ACTIVITIES Net Cash Provided by (Used in) Continuing Operations NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash (used in) investing activities Net Income (Loss) Available to Common Stockholders, Basic Net Loss Net loss Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] CASH FLOWS (USED IN) PROVIDED BY INVESTING ACTIVITIES CASH FLOWS (USED IN) INVESTING ACTIVITIES Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other assets acquired in Cell Genesys transaction Noncash or Part Noncash Acquisition, Other Assets Acquired Principal balance of debt assumed Noncash or Part Noncash Acquisition, Debt Assumed Investment acquired through Cell Genesys transaction Noncash or Part Noncash Acquisition, Investments Acquired Liabilities acquired through Cell Genesys transaction Noncash or Part Noncash Acquisition, Value of Liabilities Assumed Nonoperating Income (Expense) [Abstract] OTHER Number of operating segments Number of Operating Segments Number of reporting segments Number of Reportable Segments Office equipment Office Equipment [Member] Future minimum lease payments Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Operating Loss Carryforwards [Table] Net operating loss carryforwards Operating Loss Carryforwards Rent expense Operating Leases, Rent Expense, Net Operating loss Operating Income (Loss) Future minimum lease payments during 2014 Operating Leases, Future Minimum Payments, Due in Three Years Future minimum lease payments during 2013 Operating Leases, Future Minimum Payments, Due in Two Years Future minimum lease payments during 2012 Operating Leases, Future Minimum Payments Due, Next Twelve Months Income Taxes Operating Loss Carryforwards [Line Items] BASIS OF PRESENTATION Other Noncash Income (Expense) Other non-cash items Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net Investment impairment charge Investment impairment charge Other Assets, Noncurrent [Abstract] OTHER ASSETS Other Nonoperating Income Other income Other Noncash Investing and Financing Items [Abstract] Noncash Investing and Financing Activities Noncash investing and financing activities Other Accrued Liabilities, Current Other accrued expenses Purchase of fixed assets Payments to Acquire Property, Plant, and Equipment Payments to Acquire Investments Purchase of investment Pension and Other Postretirement Benefits Disclosure [Text Block] RETIREMENT PLAN Plan Name [Domain] Plan Name [Axis] Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Prepaid Expense and Other Assets, Current Prepaid expenses and other assets Reclassifications Reclassification, Policy [Policy Text Block] Proceeds from Warrant Exercises Proceeds from common stock warrant exercises Proceeds from warrants exercised Proceeds from (Payments for) Other Financing Activities Cash paid for transaction related costs Proceeds from Issuance of Common Stock Proceeds from issuance of common stock by registered direct offering Net proceeds from issuance of common stock by registered direct offering after deducting placement agent fees and offering expenses Proceeds from Issuance or Sale of Equity Net proceeds from issuance of shares and warrants Proceeds from Sale of Productive Assets Proceeds from sale of fixed assets Proceeds from Sale of Short-term Investments Redemption of short term investments Proceeds from common stock option exercises Proceeds from Stock Options Exercised Estimated useful lives Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Type [Domain] PROPERTY AND EQUIPMENT Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Property, Plant and Equipment, Net PROPERTY AND EQUIPMENT, NET Property and equipment, net Property and equipment Property, Plant and Equipment [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Schedule of property and equipment, net of accumulated depreciation Property, Plant and Equipment [Table Text Block] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment Disclosure [Text Block] PROPERTY AND EQUIPMENT Purchase Obligation Remaining obligation Quarterly Financial Information [Text Block] SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) Range [Axis] Range [Domain] Research and Development Expense Research and development Research and Development Expense [Member] Research and development Research and Development Research and Development Expense, Policy [Policy Text Block] Acquired in-process research and development Research and Development in Process Acquired in-process technology Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings [Member] Accumulated Deficit Revenue from Grants Grant revenue Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Revenues Total revenue Revenue Revenues [Abstract] REVENUE Royalties on sales of products Royalty Expense Royalty Revenue Royalty revenue Exercisable at the end of the period intrinsic value (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Vested or expected to vest at the end of the period weighted average remaining term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected option life Exercisable at the end of the period weighted average remaining term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Outstanding at the end of the period weighted average remaining term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Scenario, Unspecified [Domain] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of financial assets and liabilities recorded at fair value on a recurring basis Summary of activity under the plans Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of weighted average assumptions used in estimation of the fair value of options granted Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of maturities of required principal payments by year related to the convertible senior notes Schedule of difference in the provision for income taxes computed by applying the statutory income rate to pre-tax income Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of purchase price allocation Schedule of Purchase Price Allocation [Table Text Block] Schedule of selected quarterly data Schedule of Quarterly Financial Information [Table Text Block] Schedule of the Company's net deferred tax asset Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Summary of stock option compensation expense for employees and non-employees Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of warrants to purchase common stock outstanding and exercisable Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Property, Plant and Equipment [Table] Schedule of Stock by Class [Table] Selected quarterly data Selected Quarterly Financial Information [Abstract] Senior Notes, Current Current portion of Convertible Senior Notes Current portion of convertible senior notes Severance costs Severance Costs Share-based Compensation Employee and director stock-based compensation Employee & director stock-based compensation Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected stock price volatility, maximum (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected stock price volatility, minimum (as a percent) Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Fair value of shares vested (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period of outstanding stock options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, maximum (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Options granted under the plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation Share Price Purchase price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Weighted average exercise price of options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, minimum (as a percent) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Forfeited or expired (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected stock price volatility (as a percent) Exercisable at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average fair value (in dollars per share) Intrinsic value of options exercised (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value Additional disclosure related to options Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Exercisable at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of shares that remained available for issuance under the plan Option Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares of the entity's common stock authorized for issuance under the plan Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Weighted average assumptions used in estimation of the fair value of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Forfeited or expired (in shares) Options expired and cancelled (in shares) Vested or expected to vest at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Number of shares of the common stock issued Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at the end of the period intrinsic value (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested or expected to vest at the end of the period intrinsic value (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding stock options (in shares) Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Award Type [Domain] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Vested or expected to vest at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Software Software [Member] Statement [Table] Scenario [Axis] Statement [Line Items] Statement Statements of Stockholders' Equity Condensed Statements of Cash Flows Equity Components [Axis] Condensed Balance Sheets Class of Stock [Axis] Stock Issued During Period, Shares, Period Increase (Decrease) Stock Issued During Period, Shares, Acquisitions Issuance of common shares pursuant to Cell Genesys, Inc. transaction (in shares) Stock Options [Member] Stock options Stock Issued During Period, Value, Stock Options Exercised Stock option exercise Stock Issued During Period, Value, Acquisitions Issuance of common shares pursuant to Cell Genesys, Inc. transaction Stock Issued During Period, Value, New Issues Underwritten offering of common shares, net Stock Issued Shares issued for Cell Genesys transaction Shares issued for convertible senior notes and accrued interest Stock Issued During Period, Shares, New Issues Stock issued during period (in shares) Warrants issued (in shares) Underwritten offering of common shares, net (in shares) Underwritten public offering of common stock (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options exercised (in shares) Stock option exercise (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Number of shares issued in exchange for cancellation for debt Number of shares issued in exchange for cancellation Stockholders' Equity Attributable to Parent [Abstract] STOCKHOLDERS' EQUITY Stockholders' Equity Attributable to Parent TOTAL STOCKHOLDERS' EQUITY Balance at beginning of period Balance at end of period STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY Stockholders' Equity, Period Increase (Decrease) Subsequent Events [Text Block] SUBSEQUENT EVENTS SUBSEQUENT EVENTS Subsequent Event Type [Domain] Subsequent Event [Line Items] SUBSEQUENT EVENTS Subsequent Event Type [Axis] Subsequent Event [Table] Subsequent Event [Member] Subsequent Event Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION Type of Arrangement and Non-arrangement Transactions [Axis] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average number of common and common equivalent shares outstanding: WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING Weighted Average Number of Shares Outstanding, Basic Basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Diluted (in shares) Third Amendment to License Agreement [Member] Third Amendment To License Agreement Represents information pertaining to the third amendment to license agreement. Milestone Payment Upon FDA Authorization of Marketing of Licensed Male Testosterone Gel [Member] Milestone payment upon FDA authorization of marketing of licensed male testosterone gel Represents the milestone payment upon FDA authorization of marketing of licensed male testosterone gel. Milestone Payment Upon Earlier of 31 December 2012 and Five Business Days After Submission to FDA of Final Report on Washing Clinical Study [Member] Milestone payment upon earlier of December 31, 2012 and five business days after submission to FDA of final report on washing clinical study Represents the milestone payment upon earlier of December 31, 2012 and five business days after submission to FDA of final report on washing clinical study. Milestone Payment Upon Earlier of 31 December 2013 and Five Business Days After Commencement of Commercial Manufacture of Licensed Product [Member] Milestone payment upon earlier of December 31, 2013 and five business days after commencement of commercial manufacture of licensed product for sale in the United States Represents the milestone payment upon earlier of December 31, 2013 and five business days after commencement of commercial manufacture of licensed product for sale in the United States. Payment for Being Sole Marketer in US of 1 Percent Testosterone Gel for Atleast 180 Days Immediately Following Launch in US [Member] Payment for being the sole marketer in the United States of a generic 1% testosterone gel AB-rated to AndroGel for at least 180 days immediately following the launch date of the licensed product in the United States Represents the payment for being the sole marketer in the United States of a generic 1 percent testosterone gel AB-rated to AndroGel for at least 180 days immediately following the launch date of the licensed product in the United States. Collaborative Arrangement Potential Milestone Payments Receivable Aggregate amount receivable, if regulatory milestones are successfully achieved Represents the total amount that could be received based on certain regulatory or commercial events achieved by members to the agreement. Number of Business Days Considered in Milestone Payments Number of business days considered in milestone payments Represents the number of business days considered in milestone payments. Number of Days from Launch of Product for Which Sole Marketer Right is Given for Additional Payment Number of days from the launch of the licensed product in the United States for which sole marketer right is given for additional payment Represents the number of days from the launch of the licensed product in the United States for which sole marketer right is given for additional payment. Royalty rate as a percentage of net sales Represents the royalty rate as a percentage of net sales. Collaborative Arrangement Royalty Rate as Percentage of Net Sales Number of Directors of Entity in Board of Directors of Combined Company Number of directors of the entity in board of directors of the combined company Represents the number of directors of the entity in board of directors of the combined company. Period During which Net Cash Payments can be Received after Distribution of Rights Period during which net cash payments can be received after distribution of rights Represents the period during which net cash payments can be received after distribution of rights from contingent value rights. Net Cash Payments to be Distributed to Holders Expressed as Percentage of Net Cash Payments Received Net cash payments to be distributed to holders of the CVRs expressed as percentage of net cash payments received Represents the net cash payments to be distributed to holders of the contingent value rights expressed as percentage of net cash payments received by the entity. Aggregate Net Cash Payments to be Distributed to Holders Aggregate net cash payments to be distributed to holders of CVRs Represents the aggregate net cash payments to be distributed to holders of the contingent value rights. Net Cash Required to Obligate Entity to Effect Merger Net cash required to obligate the entity to effect merger Represents the amount of net cash required to obligate the entity to effect merger Unpaid Costs Associated With Registered Direct Offering Unpaid costs associated with registered direct offering Represents the amount of unpaid costs associated with registered direct offering in a noncash or partial noncash transaction. Shareholder derivative action Represents information pertaining to the shareholder derivative action filed against the entity. Shareholder Derivative Action [Member] Number of Cases Consolidated Number of cases consolidated Represents the number of cases that were consolidated. Business Merger Termination Fee Payable Termination fee payable under specified circumstances Represents the amount of a termination fee that may be payable on meeting of certain triggering events specified in the agreement. Business Merger Reimbursement of Expenses Reimbursement of expenses in connection with merger Represents the amount of reimbursement of expenses in connection with merger on meeting certain specified circumstances as specified in the agreement. Percentage of Outstanding Shares of Capital Stock Held by Stockholders Percentage of outstanding shares of capital stock held by stockholders as of the close of business Represents the percentage of outstanding shares of capital stock held by stockholders as of the close of business. Number of Stockholders Holding Specified Percentage of Outstanding Shares of Common Stock Number of stockholders holding 57 percent of outstanding shares of common stock Represents the number of stockholders holding specified percentage of outstanding shares of common stock as of the close of business. Percentage of Outstanding Shares of Common Stock Held by Stockholders Who Agreed to Vote in Favor of Election of Directors Percentage of outstanding shares of common stock held by stockholders who agreed to vote in favor of election of directors Represents the percentage of outstanding shares of common stock held by stockholders as of the close of business, who agreed to vote in favor of election of directors. Number of Directors Designated by Entity Number of directors designated by the entity at the first annual meeting of stockholders following the completion of the Merger Represents the number of directors designated by the entity at the first annual meeting of stockholders following the completion of the merger. Percentage of Outstanding Shares of Common Stock Held by Specified Personnel Who Entered Into Agreements Percentage of outstanding shares of common stock held collectively by specified personnel who entered into voting agreements Represents the percentage of outstanding shares of common stock held by specified personnel as of the close of business, who entered into agreements. Locking Period on Sale of Shares Post Merger Locking period on the sale of shares of the Company's common stock received in the Merger Represents the locking period on the sale of shares of the entity's common stock received in the merger. Represents the number of contingent value rights issued in exchange for one share of common stock. Number of Contingent Value Rights Issued in Exchange for One Share Number of contingent value rights issued in exchange for one share of common stock (in shares) Unpaid Costs Associated with Under Written Public Offering Unpaid costs associated with underwritten public offering Represents the amount of unpaid costs associated with underwritten public offering in a noncash or partial noncash transaction. Schedule of Stockholders Equity [Table] Represents information pertaining to changes in stockholder's equity. Represents details pertaining to warrants, which are issued to institutional investors. Warrant Issued to Institutional Investors [Member] Warrants issued to institutional investors Stockholder's equity Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Stockholders Equity [Line Items] Proceeds from Issuance of Common Stock, Gross Gross proceeds from issuance of shares Represents the gross amount of cash inflow from the additional capital contribution to the entity. Represents the term over which the warrants expire. Class of Warrant or Right Term of Warrants Term of warrants (in years) Payments to Fractional Share Payout Fractional share payout Represents payments of fractional shares as a result of reverse stock split. Fractional share payout Stockholders Equity Reverse, Stock Split Conversion Ratio Reverse stock split conversion ratio Represents the conversion ratio used in the calculation of reverse stock split. Fair Value Option Changes in Fair Value Non Cash Adjustment Additional non-cash fair value adjustment attributable to conversion of debt For each line item in the statement of financial position, the non-cash increase (decrease) in fair value resulting from transactions during the period. Period for which Cash and Cash Equivalents will Meet Liquidity Requirements Period for which cash and cash equivalents will meet liquidity requirements Represents the period for which cash and cash equivalents will meet liquidity requirements of the entity. Number of Institutional Investors to Whom Offering Made Number of institutional investors Represents the number of institutional investors to whom offerings were made to raise funds. ANI Pharmaceuticals Inc [Member] ANI Pharmaceuticals, Inc Represents the details pertaining to ANI Pharmaceuticals, Inc. Merger Agreement [Member] Agreement and Plan of Merger Represents the details pertaining to merger agreement. Voting Agreement [Member] Voting Agreements Represents the details pertaining to voting agreements. Lock Up Agreement [Member] Lock-Up Agreements Represents the details pertaining to lock-up agreements. Contingent Value Rights Agreement Contingent Value Rights Agreement [Member] Represents the details pertaining to contingent value rights agreements. Ownership Percentage of Outstanding Shares of Common Stock of Combined Company by Current Stockholders Percentage of outstanding shares of common stock of combined company owned by current stockholders Represents the percentage of outstanding shares of common stock of combined company owned by current stockholders. Teva Pharmaceuticals USA Inc [Member] Teva Represents the details pertaining to Teva Pharmaceuticals USA, Inc. Collaborative Arrangement Potential Payments Receivable for Giving Sole Marketer Right Payments receivable, if sole marketer rights are given Represents the payments receivable, if sole marketer rights are given by the entity. Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Collaborative Arrangements and Non-collaborative Arrangements [Axis] Employee Severance [Member] Employee Reduction LOSS BEFORE INCOME TAX BENEFIT Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Proceeds from Collaborators Payments received from agreements Restructuring Type [Axis] Forecast Scenario, Forecast [Member] Type of Restructuring [Domain] Pre-Effective Amendment Number